iSEARCH – Can intrapartum Sildenafil Citrate safely avert the risks of contraction-induced hypoxia in labour? A pragmatic multicentre Phase III randomised controlled trial.

See ANZCTR for full trial details >

 

Trial Summary:

To determine if, in women in labour at term receiving oral 50mg Sildenafil Citrate vs. placebo given in ≤3 doses, reduces a primary composite endpoint, determined up to 28 days after birth, of ten perinatal outcomes related to intrapartum hypoxia

Supported By:

NHMRC Medical Research Future Fund

Eligibility:

Women with singleton or twin pregnancies, planning vaginal birth at ≥37 weeks gestation

Registration ID:

ACTRN12621000231842

Participation:

Australia

Australian Lead Group:

Mater Research Institute

Status:

Recruiting

Activation:

TBC

Chairs:

Professor Sailesh Kumar

Contact:

isearch.study@sydney.edu.au